Acute Coronary Syndrome News and Research RSS Feed - Acute Coronary Syndrome News and Research

Diagnosing heart attacks in 1 hour: an interview with Dr Richard Body

Diagnosing heart attacks in 1 hour: an interview with Dr Richard Body

Cardiac troponin is a highly sensitive and specific biomarker for myocardial injury but concentrations in the blood rise over several hours after the onset of an acute myocardial infarction. [More]
Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Patients treated with CMX-2043--an investigational drug that has previously shown some ability to protect heart muscle from damage during stenting--saw no improved protection in their kidneys compared to placebo, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. [More]
Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. [More]
Routine stress adversely affects women’s heart

Routine stress adversely affects women’s heart

While the number of men dying from a heart attack has been constantly decreasing during the past twenty years, the fatal risk particularly in young women has increased significantly. Gender medicine has already demonstrated that women exhibit different symptoms. A new insight shows that stress in the daily routine has particularly adverse effects on the hearts of women. This was emphasised by Alexandra Kautzky-Willer, Professor for Gender Medicine of MedUni Vienna, on the occasion of the impending International Women's Day on 8 March 2016. [More]
Gender associated with risk of cardiovascular recurrence in adults

Gender associated with risk of cardiovascular recurrence in adults

Sex (biological and physiological characteristics) differences are increasingly being studied to assess symptoms, risk factors and outcomes for various diseases. Now, a new pan-Canadian study led by a team from the Research Institute of the McGill University Health Centre, suggests that gender rather than sex is associated with the risk of recurrence of cardiovascular events in adults. [More]
Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days. [More]
Johns Hopkins researchers present new healthcare tips from American Heart Association Meeting

Johns Hopkins researchers present new healthcare tips from American Heart Association Meeting

Linking digital activity trackers to smartphones and periodically pinging users with personalized texts that urge them to walk more can significantly increase physical activity levels and spark healthy behavior changes, according to findings of a pilot study conducted at Johns Hopkins. [More]
Infections experienced in childhood may lead to premature ACS or heart attacks

Infections experienced in childhood may lead to premature ACS or heart attacks

"Cardiovascular disease (CVD) is the number one killer worldwide, including in Indonesia where it accounts for 31.9% of all deaths," said Dr Qanitha. "CVD risk factors are rising rapidly in South-East Asia, particularly in young people. Most Indonesian CVD patients are under 56 years old and still economically productive. This very young CVD onset raises the question of whether local circumstances may play a role." [More]
Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial. [More]
Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today. [More]
ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial. [More]
ESC guideline adherent antithrombotic management improves outcomes in AF patients

ESC guideline adherent antithrombotic management improves outcomes in AF patients

Patients with atrial fibrillation who receive antithrombotic management according to ESC guidelines have better outcomes than those who do not, according to one year follow up results from the ESC's EORP-AF Pilot General Registry presented today at ESC Congress 20151 and published online in Europace. [More]
Vascular side effects prevent first-line ponatinib use in chronic phase CML

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment. [More]
Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma Corp. today reported financial results for the second quarter and six months ended June 30, 2015. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP). [More]
Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015. [More]
Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Cardiome Pharma Corp. today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor Pharmaceuticals and the Montreal Heart Institute announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine. [More]
Advertisement
Advertisement